Joe Turgeon Healthcare News

Follow[dot]Health is a news alert service for Heathcare and Healthtech. We are following 40K entities across 30M news items - with 1M items added monthly. This is selected healthcare news for Joe Turgeon, which is filed under People. There are 70 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
8/19/2021 Spectrum Pharmaceuticals, inc (SPPI) Q2 2021 Earnings Call Transcript
... call. Our second quarter financial results press release was sent out earlier this afternoon, and is available on our website at www.sppirx.com. Joining me on the call today from Spectrum Pharmaceuticals will be Joe Turgeon, President and CEO; and Dr. Francois Lebel, Chief Medical Officer. Before we get started, I ...
illinoisnewstoday.com
8/13/2021 Spectrum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Update | Financial Buzz
... month period ended June 30, 2021 and provided a corporate update. “Momentum continues to build with poziotinib and the submission of the NDA later this year is our top corporate priority,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “We are also seeking clarification on the recent CRL ...
financialbuzz.com
8/12/2021 Spectrum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Update
... month period ended June 30, 2021 and provided a corporate update. “Momentum continues to build with poziotinib and the submission of the NDA later this year is our top corporate priority,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “We are also seeking clarification on the recent CRL ...
Business Wire
8/9/2021 Manufacturing Deficiencies Delay Decision on Eflapegrastim empr.com
8/6/2021 Spectrum's Rolontis, angling to rival Amgen's Neulasta, hit with FDA rejection over manufacturing 'deficiencies' FiercePharma
8/6/2021 Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Rolontis (eflapegrastim) drugs.com
6/1/2021 Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated | 2021-06-01 | Press Releases | Stockhouse stockhouse.com
6/1/2021 Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated | Business Wire Business Wire
6/1/2021 Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated - Stocks News Feed stocksnewsfeed.com
6/1/2021 Spectrum Pharmaceuticals Announces That the ROLONTIS (eflapegrastim) Pre-Approval Inspection Has Been Initiated | Financial Buzz financialbuzz.com
5/13/2021 Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update Yahoo News
3/31/2021 Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update financialbuzz.com
3/16/2021 Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection Yahoo News
3/16/2021 Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection Business Wire
3/16/2021 Spectrum Pharmaceuticals Provides Update on ROLONTIS (eflapegrastim) Pre-Approval Inspection financialbuzz.com
3/12/2021 FDA grants fast track status to poziotinib for HER2-mutated NSCLC healio.com
3/11/2021 SPPI Stock Price Increases Over 20% Pre-Market: Why It Happened pulse2.com
3/11/2021 FDA Grants Fast Track Designation to Spectrum Pharmaceuticals’ Poziotinib Yahoo News
3/11/2021 FDA Grants Fast Track Designation to Spectrum Pharmaceuticals Poziotinib financialbuzz.com
3/11/2021 Spectrum Pharma Climbs as FDA to Fast-Track Cancer Drug Review TheStreet
11/18/2020 Spectrum Therapeutics Inc. (NASDAQ:SPPI) Announced Q3 2020 Results And Poziotinib and ROLONTIS Developement Update biopharmajournal.com
10/27/2020 FDA Delays Review of Spectrum’s Investigational Neutropenia Drug fdanews.com
10/26/2020 FDA delays decision on Spectrum Pharma's drug candidate due to travel curbs MSN
10/26/2020 Spectrum Pharmaceuticals Announces that the FDA is Deferring its Action on the BLA for ROLONTIS® (eflapegrastim) Business Wire
10/26/2020 Spectrum Pharmaceuticals Announces that the FDA is Deferring its Action on the BLA for ROLONTIS® (eflapegrastim) intellasia.net